Tocqueville Asset Management’s Fate Therapeutics FATE Stock Holding History

Tocqueville Asset Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-15,000	Closed	-$68K	–	808
2017 Q1	$68K	Hold	15,000	–	–	﹤0.01%	786
2016 Q4	$38K	Sell	15,000 -7,000	-32%	-$18.7K	﹤0.01%	792
2016 Q3	$69K	Hold	22,000	–	–	﹤0.01%	809
2016 Q2	$37K	Hold	22,000	–	–	﹤0.01%	829
2016 Q1	$40K	Sell	22,000 -78,000	-78%	-$161K	﹤0.01%	846
2015 Q4	$337K	Sell	100,000 -4,000	-4%	-$16.8K	﹤0.01%	746
2015 Q3	$554K	Buy	104,000 +4,000	+4%	+$27.3K	0.01%	675
2015 Q2	$647K	Buy	+100,000	New	+$598K	0.01%	654

Other funds holding FATE

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Tocqueville Asset Management's FATE Position: Q2 2017 in Review

Tocqueville Asset Management sold out of Fate Therapeutics (FATE) in Q2 2017, closing a stake of 15,000 shares — an estimated $68K sold.

Tocqueville Asset Management first reported a position in FATE in Q2 2015 and held it in 8 quarters. The position peaked at $647K in Q2 2015. 60 funds tracked by Wall St. Rank hold FATE as of Q2 2017.

Tocqueville Asset Management reported no remaining Fate Therapeutics position as of Q2 2017 after selling out during the quarter.
Tocqueville Asset Management sold 15,000 Fate Therapeutics shares in Q2 2017, an estimated $68K.
Tocqueville Asset Management first reported a position in Fate Therapeutics in Q2 2015 and held it in 8 quarters.
Tocqueville Asset Management's Fate Therapeutics position peaked at $647K in Q2 2015.
60 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2017.

Based on Tocqueville Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.